TY - JOUR
T1 - Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma
AU - Maziarz, Richard T.
AU - Hao, Yanni
AU - Guerin, Annie
AU - Gauthier, Genevieve
AU - Gauthier-Loiselle, Marjolaine
AU - Thomas, Simu K.
AU - Eldjerou, Lamis
N1 - Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2018/5/4
Y1 - 2018/5/4
N2 - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.
AB - This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.
KW - Diffuse large B-cell lymphoma
KW - allogeneic hematopoietic stem cell transplant
KW - economic burden
KW - healthcare costs
KW - healthcare resource utilization
UR - http://www.scopus.com/inward/record.url?scp=85029724172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029724172&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1375100
DO - 10.1080/10428194.2017.1375100
M3 - Article
C2 - 28933643
AN - SCOPUS:85029724172
SN - 1042-8194
VL - 59
SP - 1133
EP - 1142
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -